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Dengue fever is a rapidly spreading
mosquito-borne viral disease. Some 40% of the
world’s population lives in disease-endemic
areas, and dengue outbreaks occur in more than
100 countries (1). Infected persons usually have
high fever, chills, frontal headache, rash, severe
myalgia, and malaise. Sometimes, the disease
goes unrecognized (2).
According to surveillance data, nearly 200,000
cases of dengue fever occur in 31 countries in
Central and South America (3); the attack rate
among disease-endemic populations may be as
high as 6,400 per 100,000 persons exposed. In
contrast to data regarding the rate of dengue
among populations in disease-endemic areas, data
on the attack rate among travelers are scarce.
The rate of dengue fever has been examined
in selected Japanese, Spanish, Swiss, and German
travelers and in U.S. troops deployed in Somalia
(4-8). The rate of dengue in these febrile patients
was 6.9% to 65%. To the best of our knowledge,
the rate of dengue fever has never been
examined prospectively in a cohort of healthy,
long-term travelers to disease-endemic areas.
The Study
The study was approved by the Helsinki
Committee of the Bnai Zion Medical Center,
which provides service to approximately 1,500
travelers per year. Each traveler is requested to
fill out a questionnaire including demographic,
itinerary, and vaccination data, which are stored
in a computerized database. The purpose of the
study was explained to the travelers, and
informed consent was obtained upon enrollment.
Serum was drawn from random volunteers
before starting the recommended vaccinations.
Eligibility for inclusion was based on a minimum
length of travel of at least 3 months and donation
of a serum sample before and after travel. One
hundred and four travelers fulfilled the inclusion
criteria. The second serum sample was taken 1 to
4 months after returning home. Travelers who
had positive dengue immunoglobulin (Ig) G
serologic results were sent a questionnaire. In
addition to demographics, the patients were
asked to indicate their destination, season and
length of stay, mosquito bites, use of repellents,
fever, chills, nausea or vomiting, muscle aches,
headache, cough, rash, or arthralgia. A case of
dengue fever was defined according to Centers
for Disease Control and Prevention (CDC)
criteria (9). An asymptomatic dengue infection
was one that met the laboratory criteria for
diagnosis without clinical signs. Confidence
intervals (CIs) were calculated with Statmate
(GraphPad Software, San Diego, CA).
After thawing, 104 posttravel serum samples
were tested for antibodies to dengue by an IgG
enzyme-linked immunosorbent assay (ELISA)
(Pan-Bio Pty, Ltd., Queensland, Australia). All
positive sera were then tested in parallel with
pretravel sera to confirm seroconversion.
Seroconverting pairs were sent to the CDC
laboratories in San Juan, Puerto Rico, for
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We tested for dengue seroconversion among 104 Israeli young adults who traveled
to tropical countries for at least 3 months. Seven (6.7%) seroconverted during travel;
four (3.8%) had immunoglobulin (Ig) M antibodies; one was symptomatic with borderline
IgM and a rise in IgG; two others (1.9%) had a rise in IgG titers, without detectable IgM.
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Table. Dengue serologic results in seroconverting Israeli travelers to tropical countries
Serum Length of Season of Disease Results
number Age/sex Destination stay (mos.) travel status IgM IgG
4 52/F Africa   3 Summer Asymptomatic Negative      40
4aa Negative    640
10 22/F Southeast Asia   6 Spring-summer Symptomatic Negative Negative
10a +/- Pos.b    160
11 21/F Southeast Asia   4 Summer-autumn Symptomatic Negative      40
11a Positive 2,560
12 25/F Southeast Asia   3 Summer-autumn Symptomatic Negative Negative
12a Positive    160
13 26/M Southeast Asia   3 Summer-autumn Symptomatic Negative Negative
13a Positive    640
14 22/M South America   6 Summer-autumn Asymptomatic Negative    160
14a Negative    640
18 21/M Southeast Asia 12 Spring-summer Asymptomatic Negative Negative
18a Positive    160
aa = after-travel sample.
bThis test was marginally positive.
confirmation and dengue IgM and IgG antibody
determination.
IgM antibody was measured as a qualitative
ELISA. An optical density of 0.2 or greater
compared with a negative control was considered
positive. The test may show some cross-
reactivity to other flaviviruses (10). IgG antibody
was measured as a quantitative ELISA using
mixed dengue antigens. This test may also show
cross-reactivity with other flaviviruses (11).
The mean age of the 104 study participants
was 22.4 ± 2.2 years. The average length of stay
abroad was 6.1 months (3 to 16 months), and the
total time abroad for all 104 travelers was 53
person-years. The average time between serum
samples was 11.1 months (4 to 22 months). The
destinations were Southeast Asia (70%), South
America (24%), Africa (4%), and both Southeast
Asia and South America (2%).
Seven travelers (6.7%; 95% CI = 2.7-13.3%)
had either an IgM antibody or a fourfold (or
greater) rise in IgG titers after the trip. The
median age of this group was 22 years, and four
travelers were women. All seven stayed at their
destinations (Table) during the summer months
(some also spent the spring or autumn there).
Their mean length of stay abroad was 5.3
months. The rates of conversion per month of
exposure by continent were as follows: Southeast
Asia, 5 (1.1%) of 451 (95% CI = 0.36-2.6%); South
America, 1 (0.6%) of 159 (95% CI = 0.02-3.5%);
and Africa, 1 (4%) of 25 (95% CI = 0.1-20.3%).
Four patients (3.8%) tested positive for
dengue IgM after travel. All four had negative
IgM dengue serologic test results before travel,
and all but one had negative IgG titers. All four
(two of them male) visited Southeast Asia, with
Thailand being the only common destination.
Two of these patients, who had traveled
separately, indicated that they became ill on the
island of Ko-Pangan. All four were engaged in
extensive outdoor activities and consequently
had mosquito exposure. All four used mosquito
repellents (containing 20% to 25% DEET), but
only three recalled being bitten by mosquitoes.
Three travelers had fever, which in two (both
female) was also accompanied by chills,
headache, and protracted fatigue. One patient
had an apparently asymptomatic infection.
Only two of the four IgM-positive patients
had received Japanese B encephalitis vaccine
after the initial blood collection, which could
have interfered with after-travel testing. Of the
three travelers who had a fourfold IgG rise, two
were asymptomatic, and one had a clinical
picture compatible with dengue fever 1 month
after arriving in Thailand. This traveler also had
a marginal IgM test. Among these three
travelers, two had received yellow fever vaccine
and one Japanese B encephalitis vaccine, which
could have interfered with after-travel testing.
Conclusions
Researchers have found that the younger the
age, the higher the rate of illness among
travelers, but dengue fever has not been
thoroughly investigated (12,13). Dengue fever
has not been reported in Israel over the last 50826 826 826 826 826 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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years, which made our group of young travelers
particularly suitable for this study. In addition,
there has been a dramatic increase in the
number of Israeli travelers to tropical areas
during the past decade. Approximately 40,000
Israelis travel to the tropics each year, more than
25,000 of whom are backpackers who travel for 3
to 12 months off the beaten track (14) and are
exposed to the same diseases as travelers from
other countries. Dengue fever has not been
mentioned as a real hazard to Israeli travelers,
despite an incidence in our study that may be as
high as the rate of malaria without prophylaxis,
and higher than the rates of hepatitis A,
giardiasis, or typhoid fever (15). Nevertheless, it
would be premature to extrapolate from our
group of youngsters traveling on prolonged
journeys, to groups with other travel character-
istics. Older and perhaps short-term travelers
may, for example, choose other tracks or adhere
more closely to recommendations regarding
insect repellents (16).
Four travelers (3.8%) of our group had IgM
antibodies, indicating acute infection. Another
traveler had symptoms of dengue fever with
borderline IgM and a rising titer of IgG, which
most probably reflected a recent infection. This
traveler could have been infected earlier during
her 6-month trip, and by the time the serum was
taken, the IgM level might have dropped. Two
additional travelers had a rise in IgG titers
without detectable IgM.
Our results are tentative, as the serologic
tests for dengue are not devoid of cross-reactivity
(11). Both IgM and IgG may cross-react with other
flaviviruses, such as Japanese B encephalitis,
West Nile encephalitis, or yellow fever. The rate
of IgG cross-reactivity between dengue infection
and Japanese B encephalitis or yellow fever
vaccine may be 17% to 40%; however, IgM cross-
reactivity was not found after vaccination
(E. Schwartz, pers. comm.). As none of our
travelers had signs of encephalitis and yellow fever
does not exist in Southeast Asia, the five
travelers with IgM antibodies (including the one
with a borderline case) contracted dengue fever.
Indeed, four of them had clinical symptoms
compatible with dengue fever. The diagnosis in
the two travelers who had a fourfold rise in IgG
titers was uncertain, since both were asymptom-
atic and had received yellow fever vaccines,
which may have caused a cross-reaction in IgG
assays. Dengue infection may be asymptomatic.
Only three of the four IgM-positive patients were
febrile; two of these also had chills. Asymptomatic
dengue, which was found in three of our patients,
has been described in populations of disease-
endemic areas but never in travelers (2,17).
Two additional points in our study deserve
comment. First, all four IgM-positive cases and
the borderline IgM case occurred in travelers to
Southeast Asia. A higher density of the vector
and virus in Southeast Asia or visits by many of
our travelers to Thai destinations—known for
their high rate of dengue (18-20)—may have
played a major role in this trend (our data are
insufficient to permit conclusions regarding
travel to Africa and South America). Secondly,
all seven cases occurred during the summer, a
season known for its high rate of mosquito
activity and dengue transmission. The rate of
dengue fever among travelers has been studied
by four groups of researchers (4-7); an additional
group described dengue in U.S. troops deployed
in Somalia (8). The rate of dengue in their
cohorts was 6.9% to 65%. However, all of these
researchers focused on febrile patients with
either fever of unknown origin, suspected
dengue, or malaria. Hence, it is impossible to
extrapolate from their data the actual risk of
acquiring dengue during travel to the tropics.
Other travel clinics in Israel also have
indicated that (after malaria) dengue is the
second most frequent cause of hospitalization of
returning travelers (20). Based on a minimum
figure of the four IgM-positive patients, the
calculated risk for dengue during a 1-month trip
is thus 630 out of 100,000 travelers, which puts
dengue high on the list of diseases contracted in
the tropics. This statement holds true at least for
Israeli travelers to the Far East. As patients may
be evacuated because of dengue fever or may
become sick after returning home, physicians
need to be all the more vigilant in the face of this
diagnostic possibility.
We conclude that dengue fever is perhaps the
most common mosquito-borne disease of long-
term young travelers, particularly those visiting
Southeast Asia. The present results should serve
as a further impetus toward the development of a
vaccine for dengue fever.
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